Cognition Therapeutics (CGTX) Net Cash Flow (2020 - 2026)
Cognition Therapeutics (CGTX) reported Net Cash Flow of -$5.8 million for Q1 2026, up 32.7% year-over-year from -$4.4 million in Q1 2025, and down 103.92% on a QoQ basis from -$2.8 million in Q4 2025.
Cognition Therapeutics (CGTX) has 7 years of Net Cash Flow data on file, last reported at -$5.8 million in Q1 2026.
- Quarterly Net Cash Flow rose 32.7% year-over-year to -$5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.8 million (up 181.07% YoY) and the FY2025 annual result came in at $12.0 million, up 344.07% from the prior year.
- Net Cash Flow fell to -$5.8 million in Q1 2026 per CGTX's latest filing, from -$2.8 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $28.3 million in Q3 2025 and bottomed at -$8.6 million in Q1 2025.
- The 5-year median for Net Cash Flow is -$3.2 million (2022), against an average of -$1.4 million.
- The widest annual swing landed in 2023, when Net Cash Flow slumped 601.43%; it then jumped 533.39% in 2025.
- Tracing CGTX's Net Cash Flow over 5 years: stood at -$5.1 million in 2022, then surged by 39.69% to -$3.0 million in 2023, then jumped by 198.39% to $3.0 million in 2024, then tumbled by 194.46% to -$2.8 million in 2025, then sank by 103.92% to -$5.8 million in 2026.
- Per Business Quant, the three latest CGTX Net Cash Flow figures stand at -$5.8 million (Q1 2026), -$2.8 million (Q4 2025), and $28.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 625.70 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 457.40 Mn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | -152.20 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 60.68 Mn |
| 10 | Cognition Therapeutics | 648,270.00 | 648,270.00 | - | -5.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.78 Mn |
| Mar 31, 2026 | -5.78 Mn |
| Dec 31, 2025 | -2.83 Mn |
| Dec 31, 2025 | -2.83 Mn |
| Sep 30, 2025 | 28.27 Mn |
| Sep 30, 2025 | 28.27 Mn |
| Jun 30, 2025 | -4.87 Mn |
| Jun 30, 2025 | -4.87 Mn |
| Mar 31, 2025 | -8.58 Mn |
| Mar 31, 2025 | -8.58 Mn |
| Dec 31, 2024 | 3.00 Mn |
| Dec 31, 2024 | 3.00 Mn |
| Sep 30, 2024 | -6.52 Mn |
| Sep 30, 2024 | -6.52 Mn |
| Jun 30, 2024 | -6.14 Mn |
| Jun 30, 2024 | -6.14 Mn |
| Mar 31, 2024 | 4.75 Mn |
| Mar 31, 2024 | 4.75 Mn |
| Dec 31, 2023 | -3.05 Mn |
| Dec 31, 2023 | -3.05 Mn |
| Sep 30, 2023 | -4.22 Mn |
| Sep 30, 2023 | -4.22 Mn |
| Jun 30, 2023 | -1.62 Mn |
| Jun 30, 2023 | -1.62 Mn |
| Mar 31, 2023 | -2.76 Mn |
| Mar 31, 2023 | -2.76 Mn |
| Dec 31, 2022 | -5.05 Mn |
| Dec 31, 2022 | -5.05 Mn |
| Sep 30, 2022 | 842,000.00 |
| Sep 30, 2022 | 842,000.00 |
| Jun 30, 2022 | -5.74 Mn |
| Jun 30, 2022 | -5.74 Mn |
| Mar 31, 2022 | -3.21 Mn |
| Mar 31, 2022 | -3.21 Mn |
| Dec 31, 2021 | 46.46 Mn |
| Dec 31, 2021 | 46.46 Mn |
| Sep 30, 2021 | -3.01 Mn |
| Sep 30, 2021 | -3.01 Mn |
| Jun 30, 2021 | -2.07 Mn |
| Jun 30, 2021 | -2.07 Mn |
| Mar 31, 2021 | 8.18 Mn |
| Mar 31, 2021 | 8.18 Mn |
| Dec 31, 2020 | -35,000.00 |
| Dec 31, 2020 | -35,000.00 |